

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Stereochemical Assignment of Strigolactone Analogues Confirms Their Selective Biological Activity

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1533499> since 2017-11-20T18:06:42Z

Published version:

DOI:10.1021/acs.jnatprod.5b00557

Terms of use:

Open Access


Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **ABSTRACT:** Strigolactones (SLs) are new plant hormones with various developmental
2 functions. They are also soil signalling chemicals that are required for establishing beneficial
3 mycorrhizal plant/fungus symbiosis. In addition, SLs play an essential role in inducing seed
4 germination in root-parasitic weeds which are one of the seven most serious biological threats to
5 food security. There are around 20 natural SLs that are produced by plants in very low quantities.
6 Therefore, most of the knowledge of SLs signal transduction and associated molecular events is
7 based on the application of synthetic analogues. Stereochemistry plays a crucial role in the
8 structure-activity relationship of SLs as compounds with unnatural D-ring configuration may
9 induce biological effects that are unrelated to SLs. We have synthesized a series of strigolactone
10 analogues, whose absolute configuration has been elucidated and put in relation with their
11 biological activity, thus confirming the high specificity of the response. Analogues bearing the
12 R-configured butenolide moiety showed enhanced biological activity which highlights the
13 importance of this stereochemical motif.

14

1 Strigolactones (SLs) are a new class of plant hormones whose potential in agricultural
2 applications has been fuelling intense applied and pure research, both applied and pure.¹ They
3 have recently been assessed as a new class of plant hormones having effects on shoot branching²,
4 root development,³ photomorphogenesis,⁴ besides acting as signalling molecules in the
5 rhizosphere where they induce hyphal branching in arbuscular mycorrhizal fungi (AMF)⁵ and
6 seed germination in parasitic plants.⁶ Natural SLs all share the same basic framework which
7 consists of a tricyclic ABC nucleus connected with a butenolide moiety (D-ring) by means of an
8 enol ether bridge (Figure 1).^{1b} They can therefore, be classified as Michael acceptors. More than
9 20 natural SLs have been identified^{1a,7} while it is likely that others will be found in the near
10 future. This leads to questions as to why plants produce blends of SLs and whether quantitative
11 and qualitative differences in SL production and/or exudation are important in host recognition.⁸
12 More recently still, SLs and analogues have even been shown to act as promising anticancer
13 agents.^{9,10} Strigolactones are very active molecules and indeed occur in very low abundances in
14 root exudates, which is why assessments of their biological activity and unambiguous
15 configurational assignments are often hampered.^{1a} The structural characterization of natural SLs
16 and extensive structure-activity studies (SAR) have revealed that the bioactive residue resides in the
17 CD-ring (Figure 1) portion of the molecule. This has enabled the design and synthesis of SL
18 analogues that show much simpler structures than natural SLs but still retain their bioactivity.¹¹
19 Most natural SLs show (2'R) absolute configuration while the correct configuration of (-)-
20 orobanchol (**3**) has recently been unequivocally confirmed.¹² It is now generally accepted that
21 SLs can be stereochemically grouped into two families (Chart 1), one in which the configuration
22 of the BCD-ring system is the same as (+)-strigol (**1**) and the other in which the configuration of
23 the BCD-ring system is the same as (-)-orobanchol (**3**).¹³



1
 2 **Figure 1.** General structures and configurations of some natural SLs and of the synthetic
 3 analogue (+)-GR24

4 An analysis of mutants that are insensitive to pharmacological applications of SLs has led to the
 5 identification of DAD2 in petunia as the putative receptor that is able to hydrolyze SLs.¹⁴ DAD2,
 6 AtD14 (*Arabidopsis thaliana*), and D14 (*Oryza sativa*) have been assessed by X-ray analysis
 7 and found to belong to the α,β -hydrolases family.¹⁵ In *A. thaliana*, α,β -hydrolases KAI2 and
 8 AtD14 are responsible for responses to karrikins,¹⁶ chemical compounds found in plant-derived
 9 smoke,¹⁷ and SLs respectively. It was recently demonstrated that AtD14 and KAI2 exhibit
 10 selectivity to the 2'R or 2'S strigolactone D-ring configurations, respectively. However, AtD14
 11 mediates SLs response only while KAI2 mediates responses to KARs and to some SLs
 12 analogues.¹⁸ Structure Activity Relationship studies on shoot branching inhibition in rice and
 13 Arabidopsis have recently demonstrated that the (2'R) configuration has significant influence on
 14 hormonal activity.¹⁹

1 An assessment of the configurations of SLs and analogues is therefore mandatory to avoid the
2 activation of responses that are not related to SLs and therefore the misinterpretation of our
3 results. Furthermore, the use of pure stereoisomers can furnish valuable information as to the
4 structural requirements for distinct perception systems in plants, parasitic weeds, and arbuscular
5 mycorrhizal fungi.

6 Difficulties in synthesizing natural SLs, caused by the long multistep syntheses, and their low
7 availability from natural sources have prompted chemists to develop synthetic analogues that are
8 readily accessible in sizeable quantities, stable, and whose activity may be related to that of
9 natural SLs. One added advantage of this approach is the ability to obtain more information
10 about the structural requirements for the activation of specific perception systems and the
11 specificity of the target functions. Our contribution to the field has been the development of a
12 family of indolyl derived analogues named EGOs.²⁰

13 The synthetic procedure is feasible as it starts from inexpensive reagents and multigram
14 preparations are readily accomplished. The analogues were designed with the specific aim of
15 reducing stereochemical complexity, and the only stereocenter retained is the C-2' position.
16 Compounds that are obtained as racemic mixtures are readily separated by chiral semipreparative
17 HPLC (Figure 1S, Supporting Information). Several biological assays have been carried out on
18 various target systems using EGO analogues²¹ in the past and some new ones are herein
19 presented. However, the elucidation of the absolute configuration of pure enantiomers, is
20 described here for the first time.


21 In this paper we report the assignment of the absolute stereochemistry of parent EGO10
22 compounds (**5**, **6** Figure 2) by X-ray analysis and electronic circular dichroism (ECD), and the

1 configurations of the other members of the family, by comparing ECD data is described. Once
2 the absolute configurations of the pure enantiomers are established, we then correlate some past,
3 and other unpublished results with the biological effects induced by the EGO analogues, thus
4 shedding light on the importance of configuration in SLs response. An EGO10 derivative
5 (MEB55), which is active as an anticancer agent, and some fluorescent tagged analogues
6 (EGOBP and BPGR24), which are used for bio-imaging applications, are included among the
7 analogues taken into consideration..

8 **RESULTS AND DISCUSSION**

9 **Chemistry.** Our interest in developing new synthetic SL analogues has manifested in two
10 principle aims: a) to extend the structure-activity relationship in varying systems for each of the
11 different roles ascribed to SLs, and b) to develop active fluorescent SL analogues that are
12 suitable for bioimaging studies and in vivo detection to map strigolactones distribution in plants
13 and fungi. We have recently reported the synthesis of a new class of Strigolactone analogues that
14 show interesting luminescent properties.²² We have also developed a new class of indolyl
15 derived compounds named EGO which can be functionalized with different substituents on the A
16 ring.^{21b,23} Furthermore in view of the use of SL analogues as fluorescent probes in the in vivo
17 mapping of the dynamic processes in which SLs are involved, we have designed a new
18 generation of fluorescent analogues whose properties are suitable for confocal microscopy
19 investigations using the well-known fluorescent BODIPY based probes.²⁴

1




2

3 **Figure 2.** Series of SL analogues as pure enantiomers4 EGO10 (**5**, **6**) and MEB55 (**7**, **8**) were synthesized as previously described.^{21b,23} EGOBP A (**9**)5 and EGOBP B (**10**) were synthesized and used for in vivo visualization.²² In addition, SL6 analogue GR24 (**4**) was used as the core structure due to its widespread use as a standard for

1 biological assays. The fluorophore BODIPY can be linked to GR24. To this purpose amino-
 2 GR24 (**19**, Scheme 1) was synthesized from nitro- derivative **15**, but with a slight modification to
 3 the reported procedure.²⁵ Compound **18** was obtained as a mixture of stereoisomers, more
 4 specifically as two racemic diastereomers which were separated by column chromatography.
 5 From this point onwards, the reactions were carried out on the separate diastereomers.

6 **Scheme 1.** Synthetic procedure to BPGR24 as a mixture of stereoisomers^a


7



9 ^aReagents and conditions: (i) Zn/CaCl₂, EtOH-H₂O, reflux, 2 hs (80%); (ii) *t*-Boc₂O, DMAP, THF,
 10 reflux, 18 h (80%); (iii) HCOOEt, *t*-Boc₂O, DME, rt, 2 h then 5-bromo-3-methylfuran-2(5*H*)-one, rt, 18
 11 hs (62%); (iv) TFA, DCM, rt, 2h (93%); (v), CDMT, NMM, DCM, rt, 18 h (78%).

1 After the introduction of the D-ring, compound **18** was deprotected and coupled with the
2 corresponding BODIPY fragment **20** according to the Kaminski procedure and obtained with a
3 78% yield.²⁶ The racemic mixtures were then separated via chiral HPLC (Figures 4 and 5,
4 Supporting Information) and the four stereoisomers (+) BPGR24 (**11**), (-) *ent* BPGR24 (**12**), (+)
5 2'-*epi* BP GR24 (**14**) and (-) *ent* 2'-*epi* BP GR24 (**13**) were fully characterized. The absolute
6 configurations were determined on the base of ECD data as described in the next section, and *via*
7 a comparison of chromatographic behavior with parent GR24 standards.

8 **X-ray Analysis.** Crystals of EGO10A (**5**) that were suitable for X-ray diffraction analysis were
9 obtained via the slow evaporation of a methanol solution. Since the molecule is only composed
10 of light atoms, X-ray data were collected using Cu-K α radiation ($\lambda=1.5418$ Å), which furnishes a
11 more accurate determination of absolute configuration even when heavy atoms are not present in
12 the molecule. The ORTEP plot of the molecule is shown in Figure 3.




13
14 **Figure 3.** ORTEP plot of compound EGO10A (**5**) with atom labelling. Thermal ellipsoids of
15 non-hydrogen atoms are represented at 50% probability.

16 Although the diffraction capability of the crystal was low, the data collected were sufficient to
17 unequivocally determine the absolute configuration, via the Parsons method.²⁷ As shown in

1 **Figure 3** the resulting absolute configuration of compound EGO10A is *R* at the C-1 (C-2')
2 stereocenter.²⁸

3 **ECD Measurements.** The ECD spectra of submillimolar solutions of each of the EGO10 (**5, 6**)
4 and EGOBP (**9, 10**) stereoisomer were recorded in MeCN, in order to collect evidence for the
5 absolute configuration of the C2' stereocenter.



6
7 **Figure 4** - Panel A: ECD spectra of EGO10 A (**5, a**) and B (**a'**), EGOBP A (**9, b**) and B (**10, b'**),
8 MEB 55 A (**7, c**) and B (**8, c'**); Panel B: ECD spectra of BPGR24 (**11, d**) *ent*-BPGR24
9 (**12, d'**), *ent*-2'-epi-BPGR24 (**13, e**) and 2'-epi-BPGR24 (**14, e'**). *R* stereoisomers at C-2'
10 are outlined in black; *S* stereoisomers at C-2' are outlined in dark grey. All stereoisomers
11 were dissolved in MeCN at submillimolar concentration.


12
13 Figure 4 (**panel A**) shows the ECD spectra of enantiomers A and B of EGO10, EGOBP and
14 MEB55 in the 200-300 nm region. All these compounds contain a single C-2' stereocenter.

1 Labels A and B were initially assigned according to enantiomer HPLC behaviour: the A species
2 eluted before the B species in our experimental conditions (see HPLC chromatograms in Figures
3 1S-5S in Supporting Information). The spectroscopic patterns associated with the three
4 'stereoisomers A' share similar features, and the same is true for the 'stereoisomers B' set. The
5 full ECD spectra of these compounds in the 200-450 nm range are reported in the Supporting
6 Information (Figures 6S and 7S). The stereochemical assignments of SLs stereocenters by ECD
7 spectroscopy generally relies on the empirical rule proposed by Frischmuth *et al.*²⁹ According to
8 this rule, compounds that exhibit a negative Cotton effect around 270 nm have a 2'*R*
9 configuration, whereas a positive Cotton effect band is typical of 2'*S* configuration. The rule is
10 grounded on two basic assumptions: i) an absence of electronic interactions between
11 chromophoric systems C and D; ii) the conformational identity of C-2' epimers. According to
12 these assumptions, rings C and D provide independent contributions to the ECD spectrum and
13 the region around 270 nm is mainly related to electronic transitions that involve the ring D
14 chromophore. Despite the clearly approximate character of such assumptions, the rule has proven
15 to be effective for a number of strigolactone stereoisomers.³⁰ As far as EGO10, EGOBP and
16 MEB55 compounds are concerned, stereoisomers A exhibit a negative Cotton effect band
17 around 270 nm; hence, according to Frischmuth's rule, the absolute configuration of the C-2'
18 center is *R* in all three compounds, whereas stereoisomers B possess a C-2'*S* absolute
19 configuration. This assignment is supported and confirmed by a number of consistent pieces of
20 evidence. In fact, the X-ray structure of EGO10 A (**5**) unambiguously shows a C-2'*R*
21 configuration. In addition, the three stereoisomers that belong to set A are chemically correlated,
22 in that they are obtained via a synthetic procedure that cannot perturb stereocenter C-2'. The
23 same is true for set B. Hence each set must share the same absolute configuration at C-2'.


1 Further supporting evidence is the fact that the chromatographic behavior of stereoisomers A
2 stereoisomers A vs. B towards chiral phases is homogeneous within sets. This argues in favour
3 of the same C-2' absolute configuration in each set of molecules. All the evidence collected for
4 EGO10, EGOBP and MEB55 is consistent with the assignment of the C-2'*R* configuration to set
5 A and the C-2'*S* to set B. Figure 4 (**panel B**) shows the ECD spectra of the four diastereoisomers
6 BPGR24 (**11**), *ent*-BPGR24 (**12**), 2'-*epi*-BPGR24 (**14**) and *ent*-2'-*epi*-GR24 (**13**, Figure 2). These
7 compounds exhibit peculiar ECD spectral patterns, unlike the previous sets of molecules as do
8 other known strigolactones. In particular, no sign inversion is observed for the Cotton effect in
9 the 200-350 nm range and the Frischmuth's rule is no longer applicable. This is probably related
10 to the disappearance of the premises upon which the rule was grounded: either conformational
11 issues influence the spectral pattern or the claimed electronic independence of ring C and D can
12 no longer be assumed. A completely unambiguous assignment of the absolute configuration in
13 the presence of conformational or electronic factors may require a complex approach, based on
14 the combination of ECD, VCD and theoretical calculation.³¹ Nevertheless, the combination of
15 several distinct experimental findings (X-ray structure, ECD data, chemical correlation, and
16 chromatographic behaviour) provides sufficient evidence for configurational assignment by
17 analogy. In fact, as these compounds are GR24 derivatives, ECD spectra may be analyzed by
18 comparison with the well-known CD patterns of GR24 and its diastereoisomers³²(see Figure 7S,
19 Supporting Information) which do not follow Frischmuth's rule either. (+) GR24 (**4**) has been
20 definitely shown by Scaffidi and coworkers to display a C-2'*R* configuration and its ECD
21 spectrum exhibits a positive Cotton effect in the 210-260 nm range. Both BPGR24 (**11**) and *ent*-
22 2'-*epi*-BPGR24 (**12**) show positive Cotton effect in the very same spectral region, which would
23 suggest an analogous C-2'*R* configuration for both of them. The distinct features of the ECD

1 patterns of diastereoisomers BPGR24 (**11**) and *ent-2'-epi*-BPGR24 (**12**) are certainly related to
2 differences in the electronic energy levels: *ent-2'-epi*-BPGR24 (**13**) exhibits three resolved
3 Cotton effect while BPGR24 (**11**) shows only two. However, the Cotton effect at ~230 nm is
4 clearly not a pure Gaussian curve, which means that it is the convolution of more than one
5 contribution. Hence, the ECD spectra of BPGR24 and *ent-2'-epi*-BPGR24 are consistent overall.
6 Further arguments in support of the C-2'R assignment for BPGR24 and *ent-2'-epi*-BPGR24 are
7 the chemical correlation between these two stereoisomers and (+)-GR24 as well as analogies in
8 the chromatographic behaviour of the species. In conclusion, ECD data collected on the EGO
9 and BPGR24 series of strigolactones clearly show that EGO derivatives fulfil Frischmuth's rule,
10 whereas BPGR24 derivatives do not. Experimental evidence converges towards the assignment
11 of *R* configurations for the C-2' stereocenter of EGO10 A (**5**), EGO-BP A (**9**), MEB55 A (**7**),
12 BPGR24 (**11**) and *ent-2'-epi*-BPGR24 (**13**).

13 **Biological activity.** The simplest molecules that were separated as pure enantiomers were
14 EGO10 A (**5**) and EGO10 B (**6**) whose absolute configuration corresponds to *R* for EGO10 A
15 and *S* for EGO10 B, as demonstrated by X-ray analysis and ECD data.



1
2 **Figure 5.** Bar graph representation of germinated seed percentages (Y axis) of *Phelipanche*
3 *aegyptiaca* after exposure to pure enantiomers of EGO10 A and B.



4
5 **Figure 6.** Bar graph representation of hyphal branching number per hyphal apex of *Gigaspora*
6 *margarita* after exposure to the two pure enantiomers of EGO10 A (R) and EGO10 B (S).


7 **Figures 5 and 6** clearly show that enantiomers EGO10 A and EGO10 B exhibit significantly
8 different activity in the hyphal branching test, EGO10 A (R) is the most active, while conversely,

1 the activity of these enantiomers on *Peliphanche aegyptiaca* seeds does not show any statistical
2 difference.

3 This result is consistent with the recently reported data, according to which the non-natural
4 enantiomer of SLs can activate biological responses through perception systems unrelated to
5 SLs.³²

6 **Root Hair Elongation.** The hormonal activity of the enantiomers of EGO10 on root hair
7 elongation has also been evaluated on *Arabidopsis thaliana*, using a well-established protocol.³³


8 Racemic EGO10' s strong positive effect on RH elongation has already been demonstrated.³⁴



9
10 **Figure 7.** Root hair length (µm) in root segments of *Arabidopsis thaliana* after exposure to
11 EGO10 A (*R*) and EGO10 B (*S*), EGO10-mD at 0.1 µM concentration.

12 As shown in the bar graph in Figure 7, the effect of EGO10A (*R*) is statistically larger than that
13 of its enantiomer EGO10B (*S*). In addition the effect of EGO10 without the D-ring (EGO10-mD)
14 was considered in order to demonstrate the role of the enol ether bridge and the D-ring in
15 inducing biological effects. In fact, EGO10-mD was as ineffective as EGO10 B.

1 **MEB55**. Thiophene derivatives were synthesized according to known procedure and separated
2 into pure enantiomers (see Figure 2S, Supporting Information). The activity of racemic
3 mixtures of MEB55 had already been tested on *Peliphanche aegyptiaca* seeds and good activity
4 was reported.²³
5 We next measured the activity of enantiomers at the same concentration at which the racemic
6 mixture proved to be most active. As shown in Figure 8 the two enantiomers behave differently,
7 MEB55 A (**7**, 2'*R*) is much more active than both MEB55 B (**8**, 2'*S*) and racemic GR24 which
8 was used as a standard.




9
10 **Figure 8.** Bar graph representation of percentages of germinated (Y axis) of *Peliphanche*
11 *aegyptiaca* seeds after exposure to pure enantiomers of **MEB55 A** (**7**, *R*) and **B** (**8**, *S*) at 0.1 μ M
12 concentration.

13
14 We recently reported the antiproliferative activity of some SL analogues.⁹ After an initial
15 screening of EGO10 derivatives with various substitutions on the A ring, those with a thienyl

1 (MEB55) and dioxathienyl substituent at C-7 were found to be the most potent and promising
2 candidates for anticancer therapy due to their ability to specifically induce cell cycle arrest,
3 cellular stress, and apoptosis in cancer line cell with minimal effects on normal cells growth and
4 survival. Two different cell lines have been tested for their response to enantiopure SL
5 analogues. The first line BJ is a normal cell line established from human neonate fibroblasts
6 (skin, foreskin), while the second MDA-MB-231 is from human breast cancer cells (epithelial,
7 adenocarcinoma disease).⁹ Enantiomer activity on cell lines was quantified as the effect on cell
8 viability, using XTT (see Experimental Section). As shown in Figure 9, the normal cell line BJ is
9 insensitive to the application of SL analogue application while the viability of the tumour cell
10 line MDA-MB-231 is affected by SLs. In particular, one of the two enantiomers MEB55 A (**7**),
11 which corresponds to the 2'R configuration (red bar, Figure 7) was found to be much more active
12 than the S stereoisomer. The racemic mixture (purple bar, Figure 9) and the equimolar mixture
13 of R and S enantiomers, created in order to have an additional control (light blue), show activity
14 which is similar to the most active R enantiomer indicating that the S enantiomer does not
15 possess antagonist activity.

16




1
 2 **Figure 9.** Bar graph representation of cell viability test on cell lines BJ and MDA-MB-231 in the
 3 presence of MEB55 (2500 were seeded per line). These were treated with a 7.5 μ M solution of
 4 compound MEB55 after one day. XTT measurements for the determination of cell viability were
 5 carried out 48h-after exposure to compound MEB55.

6 **EGOBP.** Spatial hormone distribution is actively regulated by plants at multiple levels, such as
 7 biosynthesis, catabolism, and transport to allow specific function to occur. The level of SL
 8 secretion is also likely to be properly controlled. The *Petunia hybrid* ABC transporter PDR1 has
 9 recently been isolated.³⁵ However, only little is known about the dynamic distribution of SLs,
 10 their precursors, and their derivatives in *Arabidopsis* in particular.³⁶ As part of our work on the
 11 synthesis of fluorescent tagged SL analogues to map the distribution of SLs in plants we
 12 synthesized EGO10 derivatives by linking the EGO10 core to a fluorescent BODIPY based
 13 probe, through a 3-carbon linker (Figure 2, EGO BP A **9** and EGO BP B **10**). The activity of
 14 racemic EGO BP had previously been tested on *Peliphanche aegyptiaca* seeds and found to be a

1 little lower than rac-GR24,²⁰ as expected. Racemic EGOBP was resolved in the two enantiomers
2 EGOBP A (**9**) and EGOBP B (**10**) whose absolute configuration was unambiguously assessed
3 according to ECD data and chiral HPLC behaviour (SI); EGOBP A being the *R* and EGOBP B
4 the *S* enantiomer. Fluorescence emission measurements of *A. thaliana* seedlings treated with
5 fluorescent SLs showed a higher accumulation of EGOBP A than EGOBP B in the root.
6 Moreover EGOBP A was the most active root hair elongation analogue. Controls were
7 performed using fluorophore BODIPY(naked-BP) alone which led to non-specific tissue
8 distribution and with EGOBP which was missing the D-ring and the enol ether connecting bridge
9 which also lead to nonspecific distribution. Given these preliminary but clear-cut results EGOBP
10 A was then chosen as the lead candidate with which to follow the distribution and transport of
11 SLs in *Arabidopsis*.³⁷

12 **BPGR24.** Because of its widespread use and the huge body of data available on its biological
13 activity in different organisms we functionalized the universal standard GR24 with the same
14 fluorescent probes BODIPY and assessed the bioactivity of the four stereoisomers (Figure 2).



15

1 **Figure 10.** Bar graph representation of percentages of germinated seeds (Y axis) of *Peliphanche*
2 *aegyptiaca* after exposure to pure enantiomers of the GR24 BP serie at 0.1 μ M concentration
3 The germination stimulatory activity of all four GR24 BP stereoisomers was measured towards
4 *Peliphanche aegyptiaca* seeds. The results shown in Figure 10 surprisingly revealed that the D1
5 diastereoisomer is completely inactive and statistically comparable to the negative control
6 acetone, whether used as a racemic mixture or a pure enantiomer. It is worthwhile emphasizing
7 that GR24, whether used as a racemic or a pure enantiomer (*rac*-GR24 vs. (+) GR24 and (-) *ent*
8 GR24) shows the predicted germination activity. Besides, the D2 diastereoisomers show
9 germination activity that is comparable to *rac*-GR24 both as racemate and as pure enantiomer
10 (2'-epi BPGR24 **14** and *ent*-2'-epi GR24BP **13**). This was then chosen as the lead candidate for
11 bioimaging studies into SL transport and distribution in living organisms.³⁸

12 In this study, the absolute configuration of a series of enantiomerically pure SL analogues by
13 means of X-ray analyses of one of the compounds and by the comparative analysis of the ECD
14 spectra of all family members were elucidated. This was based on the fine correlations found
15 within the whole family of compounds and with the literature data.

16 Recent findings demonstrate that configuration at C-2' position (D-ring) plays a crucial role in
17 the activation of specific SL related responses.³² As configuration has been proven to be a
18 significant determinant of SL activity, we examined multiple physiological responses in various
19 organisms in order to correlate absolute configuration to activity. We use parasitic seeds
20 germination (*Peliphanche aegyptiaca*), hyphal branching (*Gigaspora margarita*), root elongation
21 (*Arabidopsis thaliana*), and cell cycle arrest of cancer and non-cancer cell lines as the biological
22 targets. Wherever selectivity towards one of the two enantiomers is observed, the enantiomer

1 with 2'*R* configuration is the most active. In the Orobanchaceae, *S. hermontica* seeds are reported
2 to respond to all stereoisomers of GR24^{1a} and deoxystrigol³⁰ with a slight preference for isomers
3 with the same configuration as natural strigol. The four stereoisomers of deoxystrigol have
4 recently been tested on *Orobanche minor* and it was found that the stereoisomer with the same
5 configuration as orobanchol was the most active while its enantiomer the least so.³² However, 2'-
6 *epi* BPGR24 (**14**, 2' *S*) is the most active fluorescent derivative of GR24.

7 In summary, the present work represents an elucidation of the absolute configurations of some of
8 the most potent SL analogues that have been designed for specific purposes, and the correlation
9 between stereochemistry and biological response.

10 **EXPERIMENTAL SECTION**

11 **General Experimental Procedures.** ¹H NMR and ¹³C NMR spectra were recorded on a Bruker
12 Avance-200 spectrometer. ¹H NMR spectra were recorded at 200 MHz, ¹³C NMR and DEPT
13 spectra at 50 MHz. ESIMS data were recorded using an LCQ Deca XP plus spectrometer
14 (Thermo) spectrometer with an electrospray interface and ion trap as a mass analyzer; sheath gas
15 flow rate was set at 25 (arbitrary unit), auxiliary gas flow rate at 5 (arbitrary unit), spray voltage
16 at 3.25 (KV), capillary temperature at 270 °C, capillary voltage at -7 (V), and tube lens offset at
17 -60.00 (V). Nitrogen was used as a sheath and auxiliary gas. HRMS data were recorded on an
18 LTQ Orbitrap Hybrid Mass Spectrometer. MS data were recorded at an ionizing voltage of 70
19 eV. Chromatographic separations were carried out on silica gel (Merck Grade 7734, pore size 60
20 Å, 70-230 mesh); R_f values refer to TLC carried out on 0.25-mm silica gel plates (Merck F254),
21 with the same eluent indicated for the column chromatography. The enantiomers were separated
22 on either a semi-preparative and an analytical Chiralpak IC column (particle size 5 μm, Daicel,

1 Osaka, Japan). Dimensions: Analytical column 4.6 Φ x 250 mmL; Semiprep. column 10 Φ x
2 250 mmL. All the chemicals were purchased from Sigma-Aldrich and were used as received
3 unless stated otherwise. Column chromatography purifications was performed via classical
4 chromatography. Compounds **15**, **17**, **18**, and **19** were synthesized as previously reported.²⁵ The
5 glassware used for classical syntheses was heated overnight in an oven at 150°C and assembled
6 in the oven, then cooled under argon flux before starting the reactions. A Jasco P-2000
7 polarimeter was used for the determination of optical rotations. ECD measurements were
8 performed on a JASCO J-815 instrument at RT, in quartz cells with 1 mm optical path; scanning
9 speed 100 nm/min, bandwidth 1 nm.

10 **Biological Tests.** *Plant material.* Seeds of *Peliphanche aegyptiaca* were collected from field
11 grown tomato in the West Galilee in Israel. The seeds were stored in glass vials in the dark at
12 room temperature until used in germination tests. *Preparation of test solutions:* the compound to
13 be tested were weighted out accurately and dissolved in 1 mL of acetone and then diluted with
14 sterile distilled H₂O to reach the appropriate concentrations. All solutions were prepared just
15 before use. Seeds were surface sterilized and preconditioned according to the experimental
16 procedure indicated in ref. 31. Briefly, seeds were exposed to 50% (v/v) aqueous solutions of
17 commercial bleach for 5 min (2% hypochlorite) and rinsed with sterile distilled H₂O. For
18 preconditioning, seeds were sown on a glass fibre filter paper disc using a sterile toothpick
19 (approximately 20 seeds per disc), the glass fibre discs were placed on 2 filter paper discs,
20 dampened with sterile distilled H₂O and incubated at 25 °C in the dark for 6 days. The
21 preconditioned seeds were then allowed to dry completely in the laminar flow, treated with the
22 strigolactone analogue solutions and germination rate was evaluated under a stereomicroscope 7
23 days after treatment. At least 100 seeds were analyzed at each concentration, synthetic

1 strigolactone GR24 10^{-7} M was included as the positive control while an aqueous solution of
2 0.1% acetone and sterile distilled H₂O was included as the negative control. Seeds were
3 considered to be germinated if the radicle protruded through the seed coat.

4 **Fungal Material.** Spores of *Gigaspora margarita* Becker and Hall were collected from a
5 previously established trap culture of clover, sterilized with a solution of chloramine T (3% P/V)
6 and streptomycine sulphate (0,03% P/V), rinsed with distilled H₂O and placed in a Petri plate
7 filled with 0.2 % Phytigel gel (Sigma-Aldrich) containing 3 mM MgSO₄. The plates were
8 incubated vertically for 5 days at 30 °C in the dark. Paper discs (6 mm diameter), loaded with the
9 strigolactone analogue solution, were positioned on either side of the germinating hyphae tips.
10 The number of newly formed hyphal apex was recorded 24 h after treatment. GR24 10^{-7} M was
11 included as positive control, while an aqueous solution of 0.1% acetone and sterile distilled H₂O
12 was included as negative control.

13 **XTT Cell Proliferation Assay.** Cells were seeded into a 96 well plates at 2,500 cells per well in
14 triplicates in normal growing media. The following day, the media was replaced with phenol red-
15 free DMEM supplemented with 10% FBS (Foetal Bovine Serume) and 5% penicillin-
16 streptomycin solution. Cells were incubated over night at 37 °C in a humidified 5% CO₂-95%
17 air atmosphere, and then were treated as indicated below for 48h. An XTT (2, 3,-bis(2-methoxy-
18 4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium inner salt) reduction was used
19 to quantify viability according to manufacturer's instruction (Biological industries, IL). Cells
20 were incubated with XTT reagent for 2 h at 37 °C in a humidified 5% CO₂-95% air atmosphere.
21 Absorbance was recorded on a VersaMax ELISA Microplate Reader (Molecular devises, USA)
22 at 450 nm with 650 nm being the reference wavelength. Cell survival was estimated from the
23 equation: % cell survival of control= $100 \times (\text{At-Ac})(\text{treatment}) / (\text{At-Ac})(\text{control})$, where At and

1 Ac are the absorbencies (450nm) of the XTT colorimetric reaction in treated and control cultures
2 respectively minus non-specific absorption measured at 650nm. Absorbance of the medium
3 alone was also deducted from specific readings. Data points were connected by non-linear
4 regression lines of the sigmoidal dose-response relation in dose response assays.

5 *7-Amino-3,3a,4,8b-tetrahydro-2H-indeno[1,2-b]furan-2-one* (**16**): A solution of **15** (3.12 mmol,
6 0.684 g) in 4.8 mL of EtOH was added to an aqueous solution of CaCl₂ (2.18 mmol, 0.684 g in
7 3.6 mL of water) in a three-necked round bottom flask. Zn powder was then added (27.52 mmol,
8 1.80 gr) and the resulting suspension was heated to reflux temperature (80 °C) and reacted for 2
9 hours. Upon TLC control (petroleum ether/EtOAc, 1/1, R_f = 0.21), which indicated the total
10 consumption of the starting material, the reaction mixture was filtered on a Büchner funnel and
11 washed with CH₂Cl₂. The organic phases were washed with brine (1x 25 mL) and H₂O (2x 25
12 mL), dried over K₂CO₃, filtered and the solvent was evaporated. Compound **2** [0.420 g (80%
13 yield)] was obtained as a whitish solid and did not require further purification. ¹H NMR (CDCl₃,
14 200 MHz): δ 2.30 (1H, dd, J = 18 Hz, J = 5.8 Hz, H3a), 2.63-2.86 (2H, m, H3), 3.05-3.51 (2H,
15 m, H4), 3.57 (2H, br, NH₂), 5.73 (1H, d, J = 7.0 Hz, H8b), 6.61 (1H, dd, J = 2.0 Hz, J = 8.0 Hz,
16 H6), 6.71 (1H, d, J = 2.0 Hz, H8), 6.98 (1H, d, J = 8.4 Hz, H5). Spectroscopic data correspond
17 to literature reports.³⁹

18

1 *rac*- BPGR24 (and *rac* 2'- *epi* BPGR24). A solution of **20**^{21b} (0.15 mmol, 50 mg) was prepared
2 in 3 mL of DCM in a three neck round bottom flask, 2-chloro-4,6-dimethoxy-1,3,5-triazine
3 (CDMT, 0.18 mmol 32 mg) was then added and the solution was cooled to -5°C. *N*-
4 methylmorpholine (NMM) was added and the mixture reacted for 2 hours. When the TLC
5 control (petroleum ether/ EtOAc 2:3) confirmed the formation of the activated BODIPY
6 complex (approximately 2h) *rac*- amino- GR24 **19** (or *rac*- 2'-*epi*- GR24, 0.150 mmol 47 mg)
7 was added via cannula. The mixture was reacted at room temperature overnight. A 10% solution
8 of citric acid was added and the aqueous phases extracted with DCM (10 mL x3). The organic
9 phases were then dried over Na₂SO₄, and the solvent evaporated under reduced pressure. The
10 crude was purified by flash chromatography with hexanes/EtOAc 2:3 (Rf 0.20 green
11 fluorescence) to give 74 mg (78% yield) of an orange solid of BPGR24/*ent*-BPGR24.

12 Separation on chiral HPLC gives pure enantiomers.

13 BPGR24 (**11**): $[\alpha]_D^{25} + 86$ (*c* 0.2, CH₂Cl₂). ¹H NMR (CDCl₃, 200 MHz): δ_H 2.04 (5H, s, CH₃ D
14 ring and CH₂), 2.39-2.49 (14H, m, CH₃ BODIPY and CH₂), 2.98-3.06 (3H, m, H4 and CH₂),
15 3.29-3.42 (1H, m, H4), 3.88-3.97 (1H, m, H3a), 5.88 (1H, d, *J* = 7.8 Hz, H8b), 6.03 (2H, s,
16 BODIPY), 6.17 (1H, br, H3'), 6.96 (1H, br, H2'), 7.13 (1H, d, *J* = 8.0 Hz, H5), 7.47-7.56 (3H,
17 m, H6, H6' and H8). ¹³C NMR (CDCl₃, 50 MHz): δ_C 10.7 (2 CH₃ BODIPY), 14.4 (2 CH₃
18 BODIPY), 16.4 (CH₃ D- ring), 27.2 (CH₂CH₂CH₂CONH), 27.4 (CH₂CH₂CONH), 36.9
19 (CH₂CH₂CH₂CONH), 37.0 (CH₂ C-4a), 39.2 (C-3a), 85.9 (C-8b), 100.7 (C-2'), 113.2 (C-4),
20 117.5 (C-3'), 121.8 (CH-BODIPY), 122.3 (phenyl C-5), 125.6 (C-6'), 131.5 (phenyl, C-3), 135.9
21 (2C, BODIPY), 137.5 (2C, BODIPY), 138.2 (C, BODIPY), 139.3 (2C, BODIPY), 140.7 (C-4a),
22 141.0 (phenyl, C-6), 145.3 (C-8a), 151.3 (phenyl, C-8), 154.0 (C-7), 170.2, 171.5 (CONH);
23 ESIMS *m/z* 652,3 [M+Na]⁺; HRESIMS *m/z* 629.2339 (calcd for C₃₄H₃₄BF₂N₃O₆: 629,2509).

1 *ent*-BPGR24 (**12**): $[\alpha]_D^{25}$ -82 (*c* 0.2, CH₂Cl₂). ¹H NMR (CDCl₃, 200 MHz): δ_H 2.05 (5H, s, CH₃
2 D ring and CH₂), 2.39-2.51 (14H, m, CH₃ BODIPY and CH₂), 2.98-3.06 (3H, m, H4 and CH₂),
3 3.30-3.43 (1H, m, H4), 3.90-3.98 (1H, m, H3a), 5.90 (1H, d, *J* = 7.8 Hz, H8b), 6.04 (2H, s,
4 BODIPY), 6.19 (1H, br, H3'), 6.99 (1H, br, H2'), 7.14 (1H, d, *J* = 8.0 Hz, H5), 7.50-7.57 (3H,
5 m, H6, H6' and H8). ¹³C NMR (CDCl₃, 50 MHz): δ_C 10.9 (2 CH₃ BODIPY), 14.6 (2 CH₃
6 BODIPY), 16.5 (CH₃ D- ring), 27.5 (CH₂CH₂CH₂CONH), 27.6 (CH₂CH₂CONH), 37.1
7 (CH₂CH₂CH₂CONH), 37.2 (CH₂ C-4a), 39.3 (C-3a), 86.2 (C-8b), 100.9 (C-2'), 113.4 (C-4),
8 117.7 (C-3'), 121.9 (CH-BODIPY), 122.5 (phenyl C-5), 125.7 (C-6'), 131.7 (phenyl, C-3), 136.0
9 (2C, BODIPY), 137.7 (2C, BODIPY), 138.3 (C, BODIPY), 139.4 (2C, BODIPY), 140.9 (C-4a),
10 141.2 (phenyl, C-6), 145.6 (C-8a), 151.6 (phenyl, C-8), 154.1 (C-7), 170.4, 171.8 (CONH);
11 ESIMS *m/z* 652,3 [M+Na]⁺; HRESIMS *m/z* 629.1416 (calcd for C₃₄H₃₄BF₂N₃O₆: 629,2509).

12 *2'*-*epi*-BPGR24 (**14**): $[\alpha]_D^{25}$ + 148 (*c* 0.2, CH₂Cl₂). ¹H NMR (CDCl₃, 200 MHz): δ_H 2.05 (3H, s,
13 CH₃ D ring), 2.42-2.51 (16H, m, CH₃ BODIPY and 2xCH₂), 3.02-3.10 (3H, m, H4 and CH₂),
14 3.32-3.45 (1H, m, H4), 3.90-4.01 (1H, m, H3a), 5.91 (1H, d, *J* = 7.8 Hz, H8b), 6.04 (2H, s,
15 BODIPY), 6.18 (1H, br, H3'), 6.97 (1H, br, H2'), 7.16 (1H, d, *J* = 8.0 Hz, H5), 7.46-7.61 (3H,
16 m, H6,H6' and H8). ¹³C NMR (CDCl₃, 50 MHz): δ_C 10.9 (2 CH₃ BODIPY), 14.6 (2 CH₃
17 BODIPY), 16.5 (CH₃ D-ring), 27.4 (CH₂CH₂CH₂CONH), 27.6 (CH₂CH₂CONH), 37.1
18 (CH₂CH₂CH₂CONH), 37.2 (CH₂ C-4a), 39.3 (C-3a), 86.1 (C-8b), 100.9 (C-2'), 113.4 (C-4),
19 117.7 (C-3'), 121.9 (CH-BODIPY), 122.5 (phenyl C-5), 125.8 (C-6'), 131.7 (phenyl, C-3), 136.1
20 (2C, BODIPY), 137.6 (2C, BODIPY), 138.4 (C, BODIPY), 139.5 (2C, BODIPY), 140.8 (C-4a),
21 141.2 (phenyl, C-6), 145.5 (C-8a), 151.5 (phenyl, C-8), 154.2 (C-7), 170.4, 171.7 (CONH).;
22 ESIMS *m/z* 652,2 [M+Na]⁺; HRESIMS *m/z* 629,3516 (calcd for C₃₄H₃₄BF₂N₃O₆: 629,2509).

1 *ent-2'epi-BPGR24 (13)*: $[\alpha]_D^{25} - 175$ (*c* 0.1, CH₂Cl₂). ¹H NMR (CDCl₃, 200 MHz): δ_H 2.01 (3H,
2 s, CH₃ D ring), 2.38-2.48 (16H, m, CH₃ BODIPY and 2xCH₂), 2.98-3.04 (3H, m, H4 and CH₂),
3 3.29-3.40 (1H, m, H4), 3.87-3.98 (1H, m, H3a), 5.88 (1H, d, *J* = 7.8 Hz, H8b), 6.01 (2H, s,
4 BODIPY), 6.15 (1H, br, H3'), 6.94 (1H, br, H2'), 7.13 (1H, d, *J* = 8.0 Hz, H5), 7.43-7.58 (3H,
5 m, H6,H6' and H8). ¹³C NMR (CDCl₃, 50 MHz): δ_C 10.9 (2 CH₃ BODIPY), 14.6 (2 CH₃
6 BODIPY), 16.6 (CH₃ D-ring), 27.5 (CH₂CH₂CH₂CONH), 27.6 (CH₂CH₂CONH), 37.0
7 (CH₂CH₂CH₂CONH), 37.2 (CH₂ C-4a), 39.5 (C-3a), 86.0 (C-8b), 100.8 (C-2'), 113.2 (C-4),
8 117.7 (C-3'), 121.9 (CH-BODIPY), 122.4 (phenyl C-5), 125.7 (C-6'), 131.7 (phenyl, C-3), 136.2
9 (2C, BODIPY), 137.8 (2C, BODIPY), 138.4 (C, BODIPY), 139.6 (2C, BODIPY), 140.8 (C-4a),
10 141.1 (phenyl, C-6), 145.5 (C-8a), 151.4 (phenyl, C-8), 154.2 (C-7), 170.4, 171.6 (CONH).;
11 ESIMS *m/z* 652,2 [M+Na]⁺; HRESIMS *m/z* 629,2211 (calcd for C₃₄H₃₄BF₂N₃O₆: 629,2509).

12 **X-ray Analysis.** Crystals that were suitable for X-ray diffraction analyses were obtained via the
13 slow evaporation of a methanol solution. X-ray data were collected on an Oxford Diffraction
14 Gemini R-Ultra diffractometer equipped Enhanced Ultra (Cu) X-ray Source (mirror
15 monochromatized Cu-Kα radiation, λ=1.5418 Å). The ω scan was performed with a frame width
16 of 1.0°. The intensities were corrected for absorption with the numerical correction based on a
17 Gaussian integration over a multifaceted crystal model. Softwares used: CrysAlisPro (Agilent
18 Technologies, Version 1.171.37.31) for data collection, data reduction and absorption correction;
19 SHELXT⁴⁰ for data solution; SHELXL-2014/7⁴⁰ for refinement; OLEX2 (version 1.2.5)⁴¹ for
20 structure analysis and drawing preparation. All non-hydrogen atoms were anisotropically refined.
21 Hydrogen atoms were calculated and refined riding with U_{iso}=1.2 or 1.5 U_{eq} of the atom
22 connected. The absolute configuration was determined using Parson's method (Flack parameter
23 is reported on S20 of the Supporting Information).²⁷

1 **ASSOCIATED CONTENT**

2 **Supporting Information**

3 The supporting information is available free of charge on the ACS Publication website at DOI:

4 ^1H and ^{13}C NMR spectra, ECD spectra, $[\alpha]^D$ data, details and CIF file of X-ray data. The

5 **AUTHOR INFORMATIONS**

6 **Corresponding Author**

7 *E-mail: cristina.prandi@unito.it (C. Prandi).

8 *Tel: (+39) 011 6707647.

9 **Notes**

10 The authors declare no competing financial interest.

11

12 **ACKNOWLEDGMENTS**

13 We thank the Cost Association STREAM FA1206 “Strigolactones: biological roles and
14 applications”, Compagnia di San Paolo Foundation for their support (proJect SLEPS), the
15 Lagrange ProJect – CRT Foundation/ISI for their grant, the Italian Ministry of Universities and
16 Research and the Regione Piemonte. EGO thanks the European Commission for a Marie Curie
17 fellowship (FP7-PEOPLE-2012-ITN, project ECHONET “Expanding capability in Heterocyclic
18 Organic Synthesis”, project number 316379).

19

1

2 **REFERENCES**

3 (1) (a) Zwanenburg, B.; Pospíšil, T. *Mol. Plant* **2013**, *6*, 38-62; (b) Čavar, S.;
4 Zwanenburg, B.; Tarkowski, P. *Phyt. Rev.* **2014**, 691-711; (c) Yoneyama, K.; Xie, X.;
5 Yoneyama, K.; Takeuchi, Y. *Pest Manag. Sci.* **2009**, *65*, 467-470.

6 (2) (a) Gomez-Roldan, V.; Fermas, S.; Brewer, P. B.; Puech-Pagès, V.; Dun, E. A.;
7 Pillot, J. P.; Letisse, F.; Matusova, R.; Danoun, S.; Portais, J. C.; Bouwmeester, H.; Bécard, G.;
8 Beveridge, C. A.; Rameau, C.; Rochange, S. F. *Nature* **2008**, *455*, 189-194; (b) Leyser, O.
9 *Dev. Cell* **2008**, *15*, 337-338; (c) Shinohara, N.; Taylor, C.; Leyser, O. *PLoS Biol.* **2013**, *11*;
10 (d) Rameau, C.; Bertheloot, J.; Leduc, N.; Andrieu, B.; Foucher, F.; Sakr, S. *Front. Plant*
11 *Sci.* **2015**, *5*.

12 (3) (a) Koltai, H. *Ann. Bot.* **2013**, *112*, 409-415; (b) Rasmussen, A.; Depuydt, S.;
13 Goormachtig, S.; Geelen, D. *Planta* **2013**, *238*, 615-626; (c) Koltai, H. *New Phytol.* **2011**, *190*,
14 545-549.

15 (4) Urquhart, S.; Foo, E.; Reid, J. B. *Physiol. Plantarum* **2015**, *153*, 392-402.

16 (5) (a) Akiyama, K.; Matsuzaki, K. I.; Hayashi, H. *Nature* **2005**, *435*, 824-827;

17 (b) Ruyter-Spira, C.; Bouwmeester, H. *New Phytol.* **2012**, *195*, 730-733; (c) Bonfante,
18 P.; Genre, A. *Trends Plant Sci.* **2015**, *20*, 150-154.

19 (6) (a) Akiyama, K.; Hayashi, H. *Ann. Bot.* **2006**, *97*, 925-931; (b) Yoneyama,
20 K.; Xie, X.; Sekimoto, H.; Takeuchi, Y.; Ogasawara, S.; Akiyama, K.; Hayashi, H.; Yoneyama,
21 K. *New Phytol.* **2008**, *179*, 484-494; (c) Zwanenburg, B.; Mwakaboko, A. S.; Reizelman, A.;
22 Anilkumar, G.; Sethumadhavan, D. *Pest Manag. Sci.* **2009**, *65*, 478-491.


1 (7) (a) Ueno, K.; Furumoto, T.; Umeda, S.; Mizutani, M.; Takikawa, H.;
2 Batchvarova, R.; Sugimoto, Y. *Phytochemistry* **2014**, *108*, 122-128; (b) Nomura, S.;
3 Nakashima, H.; Mizutani, M.; Takikawa, H.; Sugimoto, Y. *Plant Cell Rep.* **2013**, *32*, 829-838.
4 (8) Yoneyama, K. *J.Pest. Sci.* **2010**, *35*, 348-350.
5 (9) (a) Pollock, C. B.; McDonough, S.; Wang, V. S.; Lee, H.; Ringer, L.; Li, X.;
6 Prandi, C.; Lee, R. J.; Feldman, A. S.; Koltai, H.; Kapulnik, Y.; Rodriguez, O. C.; Schlegel, R.;
7 Albanese, C.; Yarden, R. I. *Oncotarget* **2014**, *5*, 1683-1698; (b) Pollock, C. B.; Koltai, H.;
8 Kapulnik, Y.; Prandi, C.; Yarden, R. I. *Breast Cancer Res. Tr.* **2012**, *134*, 1041-1055.
9 (10) For Michael acceptors natural compounds acting as anticancer agents see Sinisi,
10 A.; Millán, E.; Abay, S. M.; Habluetzel, A.; Appendino, G.; Muñoz, E.; Tagliatela-Scafati, O.
11 *J. Nat. Prod.* **2015**, *78*, 1618-1623.
12 (11) (a) Zwanenburg, B.; Nayak, S. K.; Charnikhova, T. V.; Bouwmeester, H. J.
13 *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5182-5186; (b) Mwakaboko, A. S.; Zwanenburg, B.
14 *Plant Cell Physiol.* **2011**, *52*, 699-715.
15 (12) Ueno, K.; Sugimoto, Y.; Zwanenburg, B. *Phytochem. Rev.* **2014**, 1-13.
16 (13) Xie, X.; Yoneyama, K.; Kisugi, T.; Uchida, K.; Ito, S.; Akiyama, K.; Hayashi, H.;
17 Yokota, T.; Nomura, T.; Yoneyama, K. *Mol. Plant* **2013**, *6*, 153-163.
18 (14) Hamiaux, C.; Drummond, R. S. M.; Janssen, B. J.; Ledger, S. E.; Cooney, J. M.;
19 Newcomb, R. D.; Snowden, K. C. *Curr. Biol.* **2012**, *22*, 2032-2036.
20 (15) (a) Kagiya, M.; Hirano, Y.; Mori, T.; Kim, S. Y.; Kyojuka, J.; Seto, Y.;
21 Yamaguchi, S.; Hakoshima, T. *Genes Cells* **2013**, *18*, 147-160; (b) Zhao, J.; Wang, T.;
22 Wang, M.; Liu, Y.; Yuan, S.; Gao, Y.; Yin, L.; Sun, W.; Peng, L.; Zhang, W.; Wan, J.; Li, X.
23 *Plant Cell Physiol.* **2014**, *55*, 1096-1109.

- 1 (16) Jiang, L.; Liu, X.; Xiong, G.; Liu, H.; Chen, F.; Wang, L.; Meng, X.; Liu, G.; Yu,
2 H.; Yuan, Y.; Yi, W.; Zhao, L.; Ma, H.; He, Y.; Wu, Z.; Melcher, K.; Qian, Q.; Xu, H. E.; Wang,
3 Y.; Li, J. *Nature* **2013**, *504*, 401-405.
- 4 (17) Chiwocha, S. D. S.; Dixon, K. W.; Flematti, G. R.; Ghisalberti, E. L.; Merritt, D.
5 J.; Nelson, D. C.; Riseborough, J. A. M.; Smith, S. M.; Stevens, J. C. *Plant Sci.* **2009**, *177*, 252-
6 256.
- 7 (18) Scaffidi, A.; Waters, M. T.; Sun, Y. K.; Skelton, B. W.; Dixon, K. W.;
8 Ghisalberti, E. L.; Flematti, G. R.; Smith, S. M. *Plant Physiol.* **2014**, *165*, 1221-1232.
- 9 (19) Umehara, M.; Mengmeng, C.; Akiyama, K.; Akatsu, T.; Seto, Y.; Hanada, A.;
10 Weiqiang, L.; Takeda-Kamiya, N.; Morimoto, Y.; Yamaguchi, S. *Plant Cell Physiol.* **2015**,
11 1059-1072.
- 12 (20) Prandi, C.; Ghigo, G.; Occhiato, E. G.; Scarpi, D.; Begliomini, S.; Lace, B.;
13 Alberto, G.; Artuso, E.; Blangetti, M. *Org. Biomol. Chem.* **2014**, *12*, 2960-2968.
- 14 (21) (a) Cohen, M.; Prandi, C.; Occhiato, E. G.; Tabasso, S.; Wininger, S.; Resnick,
15 N.; Steinberger, Y.; Koltai, H.; Kapulnik, Y. *Mol. Plant* **2013**, *6*, 141-152; (b) Prandi, C.;
16 Occhiato, E. G.; Tabasso, S.; Bonfante, P.; Novero, M.; Scarpi, D.; Bova, M. E.; Miletto, I. *Eur.*
17 *J. Org. Chem.* **2011**, 3781-3793.
- 18 (22) Prandi, C.; Rosso, H.; Lace, B.; Occhiato, E. G.; Oppedisano, A.; Tabasso, S.;
19 Alberto, G.; Blangetti, M. *Mol. Plant* **2013**, *6*, 113-127.
- 20 (23) Bhattacharya, C.; Bonfante, P.; Deagostino, A.; Kapulnik, Y.; Larini, P.;
21 Occhiato, E. G.; Prandi, C.; Venturello, P. *Org. Biomol. Chem.* **2009**, *7*, 3413-3420.
- 22 (24) (a) Pereira, N. A. M.; Pinho e Melo, T. M. V. D. *Org. Prep. Proced. Int.* **2014**,
23 *46*, 183-213; (b) Ni, Y.; Wu, J. *Org. Biomol. Chem.* **2014**, *12*, 3774-3791; (c) Ptaszek,

- 1 M.: Rational Design of Fluorophores for In Vivo Applications. In *Fluorescence-Based*
2 *Biosensors: From Concepts to Applications*; Morris, M. C., Ed.; Progress in Molecular Biology
3 and Translational Science, 2013; Vol. 113; pp 59-108.
- 4 (25) Reizelman, A.; Wigchert, S. C. M.; Del-Bianco, C.; Zwanenburg, B. *Org.*
5 *Biomol. Chem.* **2003**, *1*, 950-959.
- 6 (26) Kaminski, Z. J.; Paneth, P.; Rudzinski, J. *J. Org. Chem.* **1998**, *63*, 4248-4255.
- 7 (27) S. Parsons, H. D. F. a. T. W. *Acta Cryst.* **2013**, 249-259.
- 8 (28) Crystallographic data for the structure reported in this paper have been deposited
9 with the Cambridge Crystallographic Data Centre with the CCDC number 1403160. Copies of
10 the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road,
11 Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).
- 12 (29) Frischmuth, K.; Wagner, U.; Samson, E.; Weigelt, D.; Koll, P.; Meuer, H.;
13 Sheldrick, W. S.; Welzel, P. *Tetrahedron-Asymmetr.* **1993**, *4*, 351-360.
- 14 (30) Nomura, S.; Nakashima, H.; Mizutani, M.; Takikawa, H.; Sugimoto, Y. *Plant*
15 *Cell Reports* **2013**, *32*, 829-838.
- 16 (31) Santoro, E.; Mazzeo, G.; Petrovic, A. G.; Cimmino, A.; Koshoubu, J.; Evidente,
17 A.; Berova, N.; Superchi, S. *Phytochemistry* **2015**, *116*, 359-366.
- 18 (32) Scaffidi, A.; Waters, M. T.; Sun, Y. K.; Skelton, B. W.; Dixon, K. W.;
19 Ghisalberti, E. L.; Flematti, G. R.; Smith, S. M. *Plant Physiology* **2014**, *165*, 1221-1232.
- 20 (33) Kapulnik, Y.; Delaux, P. M.; Resnick, N.; Mayzlish-Gati, E.; Wininger, S.;
21 Bhattacharya, C.; Séjalon-Delmas, N.; Combier, J. P.; Bécard, G.; Belausov, E.; Beekman, T.;
22 Dor, E.; Hershenhorn, J.; Koltai, H. *Planta* **2011**, *233*, 209-216.

- 1 (34) Cohen, M.; Prandi, C.; Occhiato, E. G.; Tabasso, S.; Winingar, S.; Resnick, N.;
2 Steinberger, Y.; Koltai, H.; Kapulnik, Y. *Mol. Plant* **2013**, *6*, 141-152.
- 3 (35) Kretzschmar, T.; Kohlen, W.; Sasse, J.; Borghi, L.; Schlegel, M.; Bachelier, J. B.;
4 Reinhardt, D.; Bours, R.; Bouwmeester, H. J.; Martinoia, E. *Nature* **2012**, *483*, 341-344.
- 5 (36) Sasse, J.; Simon, S.; Gübeli, C.; Liu, G. W.; Cheng, X.; Friml, J.; Bouwmeester,
6 H.; Martinoia, E.; Borghi, L. *Curr. Biol.* **2015**, *25*, 647-655.
- 7 (37) Fridlender, M. L., B.; Winingar, S.; Dam, A.; Kumari, P.; Belausov, E.;
8 Tsemach, H.; Kapulnik, Y.; Prandi, C.; Koltai, K. *Mol. Plant* **2015**, *in press*,
9 10.1016/j.molp.2015.1008.1013.
- 10 (38) Unpublished data
- 11 (39) Zwanenburg, B.; Thuring, J. *Pure and Applied Chemistry* **1997**, *69*, 651-654.
- 12 (40) Sheldrick, S. M. *Acta Cryst.* **2015**, *A71*, 3-8.
- 13 (41) O. V. Dolomanov, L. J. B., R. J. Gildea, J. A. K. Howard and H. Puschmann
14 *Appl. Cryst.* **2009**.
- 15
- 16
- 17
- 18
- 19
- 20
- 21

1



2